V3 loop sequence analysis of seven HIV type 1 group O isolates phenotyped in peripheral blood mononuclear cells and MT-2 cells

被引:20
作者
deJong, J
Simon, F
vanderGroen, G
Baan, E
Saragosti, S
BrunVezinet, F
Goudsmit, J
机构
[1] HOP BICHAT CLAUDE BERNARD,VIROL LAB,F-75877 PARIS 18,FRANCE
[2] INST TROP MED,B-2000 ANTWERP,BELGIUM
[3] HOP COCHIN,ICGM,INSERM,U363,F-75674 PARIS,FRANCE
关键词
D O I
10.1089/aid.1996.12.1503
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
HIV-1-infected individuals from which syncytium-inducing (SI) viruses are isolated most often progress more rapidly to AIDS than individuals carrying only non-syncytium-inducing (NSI) viruses. The syncytium-inducing capacity of virus isolates is commonly determined in conjunction to replication in MT-2 cells. Comparison of HIV-1 env sequences and a site-directed mutagenesis study have indicated that the presence of a positively charged amino acid at position 11 or 25 in the V3 loop is minimally required for the SI capacity of HIV-1 subtype B viruses. Studies have also shown a similar correlation between positively charged signature amino acids in the V3 loop and syncytium formation in MT-2 cells for HIV-1 subtypes A, D, and E. In the present study virus phenotype was determined and compared to the V3 loop sequence of seven HIV-1 group O isolates. Three of the HIV-1 group O isolates showed the NSI/non-MT-2 tropic phenotype and two showed the SI/MT-2 tropic phenotype, whereas two isolates presented an uncommon NSI/MT-2 tropic phenotype. The V3 loop of the two SI/MT-2 tropic isolates had a high net positive charge and contained a positively charged amino acid at position 11 or 25. The V3 loop of the two NSI/MT-2 tropic isolates had a low net positive charge and contained a single positively charged amino acid at position 37.
引用
收藏
页码:1503 / 1507
页数:5
相关论文
共 28 条
[1]  
ASJO B, 1986, LANCET, V2, P660
[2]   TARGET CELL-SPECIFIC DETERMINANTS OF MEMBRANE-FUSION WITHIN THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120 3RD-VARIABLE REGION AND GP41 AMINO TERMINUS [J].
BERGERON, L ;
SULLIVAN, N ;
SODROSKI, J .
JOURNAL OF VIROLOGY, 1992, 66 (04) :2389-2397
[3]   HIV-1 BIOLOGICAL PHENOTYPE AND THE DEVELOPMENT OF ZIDOVUDINE RESISTANCE IN RELATION TO DISEASE PROGRESSION IN ASYMPTOMATIC INDIVIDUALS DURING TREATMENT [J].
BOUCHER, CAB ;
LANGE, JMA ;
MIEDEMA, FF ;
WEVERLING, GJ ;
KOOT, M ;
MULDER, JW ;
GOUDSMIT, J ;
KELLAM, P ;
LARDER, BA ;
TERSMETTE, M .
AIDS, 1992, 6 (11) :1259-1264
[4]   ISOLATION AND ENVELOPE SEQUENCE OF A HIGHLY DIVERGENT HIV-1 ISOLATE - DEFINITION OF A NEW HIV-1 GROUP [J].
CHARNEAU, P ;
BORMAN, AM ;
QUILLENT, C ;
GUETARD, D ;
CHAMARET, S ;
COHEN, J ;
REMY, G ;
MONTAGNIER, L ;
CLAVEL, F .
VIROLOGY, 1994, 205 (01) :247-253
[5]   BIOLOGIC FEATURES OF HIV-1 THAT CORRELATE WITH VIRULENCE IN THE HOST [J].
CHENGMAYER, C ;
SETO, D ;
TATENO, M ;
LEVY, JA .
SCIENCE, 1988, 240 (4848) :80-82
[6]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 CLONES CHIMERIC FOR THE ENVELOPE V3 DOMAIN DIFFER IN SYNCYTIUM FORMATION AND REPLICATION CAPACITY [J].
DEJONG, JJ ;
GOUDSMIT, J ;
KEULEN, W ;
KLAVER, B ;
KRONE, W ;
TERSMETTE, M ;
DERONDE, A .
JOURNAL OF VIROLOGY, 1992, 66 (02) :757-765
[7]   MINIMAL REQUIREMENTS FOR THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 V3 DOMAIN TO SUPPORT THE SYNCYTIUM-INDUCING PHENOTYPE - ANALYSIS BY SINGLE AMINO-ACID SUBSTITUTION [J].
DEJONG, JJ ;
DERONDE, A ;
KEULEN, W ;
TERSMETTE, M ;
GOUDSMIT, J .
JOURNAL OF VIROLOGY, 1992, 66 (11) :6777-6780
[8]   ISOLATION AND PARTIAL CHARACTERIZATION OF AN UNUSUAL HUMAN IMMUNODEFICIENCY RETROVIRUS FROM 2 PERSONS OF WEST-CENTRAL AFRICAN ORIGIN [J].
DELEYS, R ;
VANDERBORGHT, B ;
VANDENHAESEVELDE, M ;
HEYNDRICKX, L ;
VANGEEL, A ;
WAUTERS, C ;
BERNAERTS, R ;
SAMAN, E ;
NIJS, P ;
WILLEMS, B ;
TAELMAN, H ;
VANDERGROEN, G ;
PIOT, P ;
TERSMETTE, T ;
HUISMAN, JG ;
VANHEUVERSWYN, H .
JOURNAL OF VIROLOGY, 1990, 64 (03) :1207-1216
[9]   SYNCYTIUM-INDUCING AND NON-SYNCYTIUM-INDUCING CAPACITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SUBTYPES OTHER THAN B - PHENOTYPIC AND GENOTYPIC CHARACTERISTICS [J].
DEWOLF, F ;
HOGERVORST, E ;
GOUDSMIT, J ;
FENYO, EM ;
RUBSAMENWAIGMANN, H ;
HOLMES, H ;
GALVAOCASTRO, B ;
KARITA, E ;
WASI, C ;
SEMPALA, SDK ;
BAAN, E ;
ZORGDRAGER, F ;
LUKASHOV, V ;
OSMANOV, S ;
KUIKEN, C ;
CORNELISSEN, M ;
BELSEY, EM ;
HEYWARD, W ;
ESPARZA, J ;
VANDEPERRE, P ;
SEMPALA, S ;
TUGUME, B ;
BIRYAHWAHO, B ;
VONBRIESEN, H ;
ESSER, R ;
GREZ, M ;
NEWBERRY, A ;
RANJBAR, S ;
TOMLINSON, P ;
BRADAC, J ;
MCCUTCHAN, F ;
LOUWAGIE, J ;
HEGERICH, P ;
LOPEZGALINDEZ, C ;
OLIVARES, I ;
DOPAZO, J ;
MULLINS, JI ;
DELWART, EL ;
BACHMANN, HM ;
HAHN, BH ;
GAO, F ;
YUE, L ;
SARAGOSTI, S ;
SCHOCHETMAN, G ;
KALISH, M ;
LUO, CC ;
GEORGE, R ;
PAU, CP ;
WEBER, J ;
CHEINGSONGPOPOV, R .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (11) :1387-1400
[10]  
FENYO EM, 1988, J VIROL, V62, P4414